Fresenius stock: analysis & valuation

FRE.DEMedical Care FacilitiesGermanyData as of Nov 15, 2026
Metrics analysis · Medical Care Facilities

Fresenius FRE.DE

Price 53.62 EUR +0.62%Market cap 30.2 bn EUR52 weeks 35.11 – 54.35
Forward P/E
13.7x
Industry 16.2x
EV/EBITDA
13.1x
Industry 12.3x
Revenue growth
5.9%
Industry 6.5%
Operating margin
9.9%
Industry 10.1%
Return on equity
8.3%
Industry 15.4%
Free cash flow yield
1.2%
Industry 3.8%

What does Fresenius do?

Fresenius is an internationally active healthcare group headquartered in Bad Homburg, Germany. The company mainly cares for severely and chronically ill patients. Its business is organized into two operating segments: Fresenius Kabi and Fresenius Helios.

Fresenius Kabi supplies intravenously administered generics, infusion solutions, clinical nutrition, biosimilars and medical technology such as infusion pumps and disposable products. Its customers are primarily hospitals and healthcare systems. Fresenius Helios operates hospitals in Germany and Spain and is financed mainly by reimbursements from payers such as health insurers. Competitively, Kabi is one of the large providers of infusion and nutrition therapy, with a broad product portfolio and global production. Helios is one of the largest private hospital operators in Europe and competes with other private, public and non-profit operators.

Score profile

Quality3.9
Valuation5.7
Growth4.8
Financial strength4.7
Momentum9.9

Rank vs. Medical Care Facilities (21 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.

Metrics compared with the industry

On profitability and quality, Fresenius ranks below average in the group Medical Care Facilities (3.9/10). On growth, the company ranks in the middle in the group Medical Care Facilities (4.8/10). On valuation (higher = cheaper), the stock ranks in the middle in the group Medical Care Facilities (5.7/10). On financial strength, Fresenius ranks in the middle in the group Medical Care Facilities (4.7/10).

MetricStockGroup medianRanking
Forward P/E13.7x16.2xbetter than 71 %
Trailing P/E19.0x19.7xbetter than 53 %
PEG ratio1.0x1.4xbetter than 74 %
EV/EBITDA13.1x12.3xbetter than 38 %
Price/sales1.3x1.3xbetter than 48 %
Price/book1.5x3.2xbetter than 92 %
Revenue growth5.9%6.5%better than 45 %
Earnings growth6.5%6.5%better than 50 %
Gross margin26.0%29.9%better than 31 %
Operating margin9.9%10.1%better than 45 %
Net margin6.6%6.6%better than 50 %
Return on equity8.3%15.4%better than 31 %
Debt/equity57.0%78.7%better than 60 %
Current ratio1.5x1.4xbetter than 74 %
Free cash flow yield1.2%3.8%better than 7 %
Dividend yield2.0%0.6%–
Payout ratio37.2%12.5%–
Beta0.770.77–

Valuation: what is Fresenius worth?

Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Fresenius a model range of 49.05 EUR to 63.41 EUR per share.

Price 53.62 EUR
Analysts 57.73 EUR
Fair value range 49.05 EUR – 63.41 EURMidpoint 56.23 EUR (+4.9% vs. price)

14 analysts, average rating “Strong buy”, average price target 57.73 EUR (+7.7%).

The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.

What the business depends on

  • Demand for infusion therapies, pharmaceuticals and clinical nutrition grows with the number of chronically and severely ill patients.
  • Hospital utilization and the reimbursement rates set by payers largely determine revenue and earnings in the hospital business.
  • Efficient production, stable supply chains and a broad portfolio of generics and biosimilars support margins in the pharmaceuticals business.

Risks

  • Healthcare policy interventions affecting reimbursement, hospital funding and price regulation can weigh on earnings over the long term.
  • Staff shortages and rising personnel and energy costs put margin pressure on hospital operations.
  • Production outages, quality defects or supply bottlenecks in sterile drugs can hurt revenue and reputation and trigger regulatory proceedings.

What to look for with Fresenius

The operating margin by segment is particularly informative because it shows how well Kabi and Helios each absorb cost, price and reimbursement pressure.

Full AI analysis of Fresenius

The AI evaluates all the numbers above and turns them into an assessment with a score, strengths and weaknesses, a fair value range and risks – from €1.99; Plus (€4.99) adds business model, moat and scenarios, Pro (€9.99) also peer comparison and reverse DCF. See an example.

Analyze a stock

Results in minutes
1 Choose a stock
2 Choose the depth

See what you get first: Example Compact (Apple) PDF Plus example (Microsoft) PDF Example Pro (NVIDIA) PDF

3 Delivery
Secure payment via Stripe Report by email + PDF No subscription

Frequently asked questions about Fresenius stock

What is the P/E ratio of Fresenius stock?

Based on expected earnings, Fresenius trades at a P/E of 13.7x, compared with a median of 16.2x for the peer group Medical Care Facilities. Based on the earnings of the last twelve months it is 19.0x. (data as of Nov 15, 2026)

Does Fresenius pay a dividend?

Yes. The dividend yield is currently 2.0%, with a payout ratio of 37.2% of earnings.

Is Fresenius stock undervalued?

Measured by valuation metrics (P/E, EV/EBITDA, price/sales, PEG), Fresenius is currently valued roughly in line with the average of the companies in the group Medical Care Facilities (valuation score 5.7 out of 10). Our model calculations (DCF and industry multiples) give a range of 49.05 EUR to 63.41 EUR per share at a price of 53.62 EUR. This is a model calculation, not an investment recommendation.

What do analysts say about Fresenius stock?

14 analysts have an average price target of 57.73 EUR (+7.7% vs. the current price); the average rating is “Strong buy”. Analyst targets are opinions and change frequently.

Comparable stocks

All information without guarantee. Metrics from public market data, updated daily; company profile written editorially with the help of AI. Not investment advice and not a solicitation to buy or sell securities.